Cyclin-dependent kinase 4/6 inhibition in cancer therapy
Author:
Publisher
Informa UK Limited
Subject
Cell Biology,Developmental Biology,Molecular Biology
Link
http://www.tandfonline.com/doi/pdf/10.4161/cc.22390
Reference9 articles.
1. Discovery of a Potent and Selective Inhibitor of Cyclin-Dependent Kinase 4/6
2. Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
3. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
4. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. An Overview of CDK Enzyme Inhibitors in Cancer Therapy;Current Cancer Drug Targets;2023-09
2. Heat shock proteins and cancer: The FoxM1 connection;Biochemical Pharmacology;2023-05
3. Research Progress of CDK4/6 Inhibitors in Digestive Tract Tumors;Advances in Clinical Medicine;2023
4. C-demethylation and 1, 2-amino shift in (E)-2-(1-(3-aminophenyl) ethylidene)hydrazinecarboxamide to (E)-2-(2-aminobenzylidene)hydrazinecarboxamide and their applications;Scientific Reports;2020-12
5. Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors;International Journal of Molecular Sciences;2020-09-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3